新型喹诺酮类药物OPC - 17116、氧氟沙星及司帕沙星对肺炎衣原体的体外活性
In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.
作者信息
Roblin P M, Montalban G, Hammerschlag M R
机构信息
Department of Pediatrics, State University of New York Health Science Center at Brooklyn 11203.
出版信息
Antimicrob Agents Chemother. 1994 Jun;38(6):1402-3. doi: 10.1128/AAC.38.6.1402.
Abstract
The in vitro susceptibilities of 12 strains of Chlamydia pneumonia to a new quinolone, OPC-17116; ofloxacin; and sparfloxacin were determined. OPC-17116 was slightly less active than sparfloxacin but more active than ofloxacin, with a MIC for 90% of strains tested and a minimal chlamydiacidal concentration for 90% of strains tested of 0.5 micrograms/ml.
摘要
测定了12株肺炎衣原体对一种新型喹诺酮类药物OPC - 17116、氧氟沙星和司帕沙星的体外敏感性。OPC - 17116的活性略低于司帕沙星，但高于氧氟沙星，其对90%受试菌株的最低抑菌浓度（MIC）和对90%受试菌株的最低杀衣原体浓度为0.5微克/毫升。
相似文献
1
In vitro activities of OPC-17116, a new quinolone; ofloxacin; and sparfloxacin against Chlamydia pneumoniae.新型喹诺酮类药物OPC - 17116、氧氟沙星及司帕沙星对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1994 Jun;38(6):1402-3. doi: 10.1128/AAC.38.6.1402.
2
In vitro activities of five quinolones against Chlamydia pneumoniae.五种喹诺酮类药物对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1992 Mar;36(3):682-3. doi: 10.1128/AAC.36.3.682.
3
Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.人型支原体、肺炎支原体和解脲脲原体对新型喹诺酮OPC 17116的敏感性
Antimicrob Agents Chemother. 1993 Aug;37(8):1726-7. doi: 10.1128/AAC.37.8.1726.
4
In vitro and in vivo activities of AM-1155, a new fluoroquinolone, against Chlamydia spp.新型氟喹诺酮类药物AM - 1155对衣原体属的体外和体内活性
Antimicrob Agents Chemother. 1997 Jun;41(6):1331-4. doi: 10.1128/AAC.41.6.1331.
5
In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.新型8-甲氧基喹诺酮BAY 12-8039对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1998 Apr;42(4):951-2. doi: 10.1128/AAC.42.4.951.
6
In vitro activity of trovafloxacin against Chlamydia pneumoniae.曲伐沙星对肺炎衣原体的体外活性。
Antimicrob Agents Chemother. 1997 Sep;41(9):2033-4. doi: 10.1128/AAC.41.9.2033.
7
Antibacterial activities of OPC-17116, ofloxacin, and ciprofloxacin against 200 isolates of Neisseria gonorrhoeae.OPC-17116、氧氟沙星和环丙沙星对200株淋病奈瑟菌的抗菌活性。
Antimicrob Agents Chemother. 1993 Oct;37(10):2244-6. doi: 10.1128/AAC.37.10.2244.
8
Susceptibilities of Mycoplasma pneumoniae, Mycoplasma hominis, and Ureaplasma urealyticum to a new quinolone, trovafloxacin (CP-99,219).肺炎支原体、人型支原体和解脲脲原体对新型喹诺酮类药物曲伐沙星（CP-99,219）的敏感性
Antimicrob Agents Chemother. 1996 Apr;40(4):1048-9. doi: 10.1128/AAC.40.4.1048.
9
Protective effects of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice.司帕沙星对白细胞减少小鼠实验性肺炎衣原体肺炎的保护作用。
Antimicrob Agents Chemother. 1994 Aug;38(8):1757-62. doi: 10.1128/AAC.38.8.1757.
10
The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.新型5-甲基取代喹诺酮OPC-17116的体外活性
J Antimicrob Chemother. 1993 Apr;31(4):497-504. doi: 10.1093/jac/31.4.497.
引用本文的文献
1
In vitro and in vivo activities of sitafloxacin against Chlamydia spp.西他沙星对衣原体属的体外和体内活性
Antimicrob Agents Chemother. 2001 Nov;45(11):3270-2. doi: 10.1128/AAC.45.11.3270-3272.2001.
2
Activity of quinolones against Chlamydia pneumoniae.喹诺酮类药物对肺炎衣原体的活性。
Drugs. 1999;58 Suppl 2:78-81. doi: 10.2165/00003495-199958002-00015.
3
Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection.每日口服格帕沙星与每日两次口服多西环素治疗沙眼衣原体宫颈感染的对比研究
Infect Dis Obstet Gynecol. 1998;6(3):109-15. doi: 10.1002/(SICI)1098-0997(1998)6:3<109::AID-IDOG3>3.0.CO;2-S.
4
In vitro activity of a new ketolide antibiotic, HMR 3647, against Chlamydia pneumoniae.新型酮内酯类抗生素HMR 3647对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1998 Jun;42(6):1515-6. doi: 10.1128/AAC.42.6.1515.
5
In vitro activity of a new 8-methoxyquinolone, BAY 12-8039, against Chlamydia pneumoniae.新型8-甲氧基喹诺酮BAY 12-8039对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1998 Apr;42(4):951-2. doi: 10.1128/AAC.42.4.951.
6
In vitro activity of trovafloxacin against Chlamydia pneumoniae.曲伐沙星对肺炎衣原体的体外活性。
Antimicrob Agents Chemother. 1997 Sep;41(9):2033-4. doi: 10.1128/AAC.41.9.2033.
7
In vitro activity of trovafloxacin (CP-99,219), sparfloxacin, ciprofloxacin, and fleroxacin against respiratory pathogens.曲伐沙星（CP-99,219）、司帕沙星、环丙沙星和氟罗沙星对呼吸道病原体的体外活性。
Eur J Clin Microbiol Infect Dis. 1996 Aug;15(8):696-8. doi: 10.1007/BF01691164.
8
Antichlamydial activities of newly developed fluoroquinolones and their potential future role in the treatment of chlamydial respiratory infections.新开发的氟喹诺酮类药物的抗衣原体活性及其在衣原体呼吸道感染治疗中未来的潜在作用。
Drugs. 1995;49 Suppl 2:257-9. doi: 10.2165/00003495-199500492-00061.
9
Antimicrobial susceptibility and therapy of infections caused by Chlamydia pneumoniae.肺炎衣原体所致感染的抗菌药敏性及治疗
Antimicrob Agents Chemother. 1994 Sep;38(9):1873-8. doi: 10.1128/AAC.38.9.1873.
本文引用的文献
1
In vitro and in vivo antichlamydial activities of newly developed quinolone antimicrobial agents.
Antimicrob Agents Chemother. 1993 Apr;37(4):801-3. doi: 10.1128/AAC.37.4.801.
2
The in-vitro activity of OPC-17116, a new 5-methyl substituted quinolone.新型5-甲基取代喹诺酮OPC-17116的体外活性
J Antimicrob Chemother. 1993 Apr;31(4):497-504. doi: 10.1093/jac/31.4.497.
3
Susceptibilities of Mycoplasma hominis, Mycoplasma pneumoniae, and Ureaplasma urealyticum to a new quinolone, OPC 17116.人型支原体、肺炎支原体和解脲脲原体对新型喹诺酮OPC 17116的敏感性
Antimicrob Agents Chemother. 1993 Aug;37(8):1726-7. doi: 10.1128/AAC.37.8.1726.
4
In vitro susceptibilities of mycoplasmas and ureaplasmas to new macrolides and aryl-fluoroquinolones.支原体和脲原体对新型大环内酯类药物及芳基氟喹诺酮类药物的体外敏感性
Antimicrob Agents Chemother. 1988 Oct;32(10):1500-2. doi: 10.1128/AAC.32.10.1500.
5
Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections.氧氟沙星治疗肺炎衣原体（TWAR株）下呼吸道感染
Am J Med. 1990 Dec;89(6):722-4. doi: 10.1016/0002-9343(90)90212-v.
6
A new respiratory tract pathogen: Chlamydia pneumoniae strain TWAR.一种新的呼吸道病原体：肺炎衣原体TWAR株。
J Infect Dis. 1990 Apr;161(4):618-25. doi: 10.1093/infdis/161.4.618.
7
Infection with Chlamydia pneumoniae in Brooklyn.布鲁克林地区肺炎衣原体感染情况。
J Infect Dis. 1991 Apr;163(4):757-61. doi: 10.1093/infdis/163.4.757.
8
Persistent infection with Chlamydia pneumoniae following acute respiratory illness.急性呼吸道疾病后肺炎衣原体的持续感染。
Clin Infect Dis. 1992 Jan;14(1):178-82. doi: 10.1093/clinids/14.1.178.
9
In vitro activities of five quinolones against Chlamydia pneumoniae.五种喹诺酮类药物对肺炎衣原体的体外活性
Antimicrob Agents Chemother. 1992 Mar;36(3):682-3. doi: 10.1128/AAC.36.3.682.
10
In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116.新型喹诺酮OPC-17116的体外和体内抗菌活性
Antimicrob Agents Chemother. 1992 Mar;36(3):573-9. doi: 10.1128/AAC.36.3.573.
Zotero 插件